# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emile Griffith (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX005-SYN-TD
- Date: 2005-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Fairbanks-Ochieng, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review of PTSD, mood and memory. **S**

## History of present illness

Emile Griffith returns with his care partner. Nightmares come about once every two weeks, and he sleeps about six and a half hours most nights. He takes sertraline 50 mg each morning without side effects and asks how long he should stay on it. He walks most mornings, does his exercises and has had no falls. He visited a boxing gym in the city twice this month to watch young fighters train. His care partner has noticed no change in his memory, and he has not been lost. No thoughts of suicide. **S**

| Element | Detail |
|---|---|
| PCL-5 | 20, from 41 at intake |
| PHQ-9 | 4; item 9 scored 0 |
| Nightmares | About once every two weeks |
| Falls | None; Timed Up and Go 10 seconds |
| Vaccines today | High-dose influenza and the second zoster dose |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Occasional nightmares; mood good; no thoughts of suicide |
| Neurological | Positive | Forgetfulness unchanged; no headaches, weakness, tremor or slowness |
| Constitutional | Negative | Weight stable; no fatigue |
| Musculoskeletal | Negative | No falls |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74.2 kg; BMI 25.7 kg/m². All vital signs are synthetic.

PHQ-9: 4; PCL-5: 20. All results are synthetic.

## Change since baseline

- PHQ-9: 9 at baseline, 4 at this visit **S**
- PCL-5: 41 at baseline, 20 at this visit **S**

## Immunizations given today

- High-dose influenza vaccine, 2005-2006 season **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and cheerful; blood pressure 126/76 mmHg; pulse 66; weight 74.2 kg |
| Musculoskeletal | Timed Up and Go 10 seconds |
| Mental status | Euthymic; tells stories with fewer repetitions; no psychotic symptoms; denies thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-traumatic stress disorder, chronic** (F43.12). PCL-5 20, below the probable-PTSD range, with PHQ-9 4. Continuing sertraline for at least six to twelve months after the response is reasonable; tapering can then be planned with him. **S**
   - Continue sertraline 50 mg; discuss a slow taper at the yearly review.
   - Booster therapy sessions if nightmares increase.
   - Safety plan and 988 reviewed.
2. **Mild cognitive impairment** (G31.84). Stable; no new safety concerns. **S**
   - MoCA and CDR at the yearly review.
   - Repeat neuropsychological testing in about a year.
   - Return sooner with any change in memory, mood, walking or behavior.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake; next at the yearly review in about six months |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | CDR 0.5 at two weeks; function unchanged |
| Survey | Neuropsychological testing | At diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with change | Up to date | Repeat due in about a year |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline 50 mg only |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Completed today | PHQ-9 4 (remission), item 9 scored 0; no thoughts of suicide |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Completed today | PCL-5 20 |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Up to date | No dose change; no side effects; sodium 137 mmol/L six weeks ago |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Completed today | Timed Up and Go 10 seconds; no falls |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | No episodes of getting lost; plans unchanged |
| Survey | Care partner support and burden (Zarit Burden Interview, narrative) | At diagnosis, then every 6 to 12 months | Completed today | Zarit 10 (little or no burden), from 14 |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Up to date | Health care proxy on file; revisit at the next annual wellness visit |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 126/76 mmHg; weight 74.2 kg |

## Goal progress

- Find the cause of the memory problems and explain it to him in a way he can take in. Outcome by 2005-06-16: Mild cognitive impairment most likely due to traumatic brain injury; explained with his care partner present, at his request, with a written summary. **S**
- A clinically meaningful fall in PTSD symptoms (PCL-5 down at least 10 points) by four months. Outcome by 2005-09-15: PCL-5 from 41 to 26 after cognitive processing therapy and sertraline. **S**
- Nightmares no more than about once a week, with at least six hours of sleep most nights. Outcome by 2005-10-27: Nightmares about once every two weeks; sleeping about six and a half hours. **S**
- No falls, with a balance and strength program. Outcome by 2005-10-27: No falls; Timed Up and Go from 13 to 10 seconds after physical therapy and a home program. **S**
- Name a health care agent and record his goals of care while he can take part fully. Outcome by 2005-08-04: Health care agent named and goals of care recorded at the annual wellness visit. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026), Aether Forge
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- STEADI (Stopping Elderly Accidents, Deaths and Injuries): Clinical Resources (2024), Centers for Disease Control and Prevention
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Yearly cognitive review with MoCA and CDR in about six months, and the annual wellness visit. COVID-19 vaccine at the pharmacy next week, at his choice. Call the clinic or 988 at any time if thoughts of suicide arise. **S**

